Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MV;DfZRwfG:6aXPpeJkh[XO|YYm= M2e0eFczKGh? MmWxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= NXPSUHRpOTl4NUS0NFg>
RS4-11 cells Ml;QSpVv[3Srb36gZZN{[Xl? M1rvRlIhcA>? NEC0XVZKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLTOE0yOSClZXzsd{Bi\nSncjCyJIhzeyCkeTDlcIVkfHKxY3jlcYltfW2rbnXzZ4Vv[2ViYYPzZZktKEmFNUC9NVMhdk1? NWC1OXZ2OTl4NUS0NFg>
CGTH-W-1 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFIvPjVizszN NH;aU|FUSU6JRWK=
SW982 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2rofGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OU42QCEQvF2= Ml\iV2FPT0WU
human EoL-1-cell cell MlXpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVrGS2FiUW6qaXLpeIlwdiCxZjDoeY1idiCHb1ytNU1k\WyuIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFghdk1? MnfWV2FPT0WU
MOLM-13 cells MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmj1O|IhcA>? NVjzUG5OUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=> NUftdlNKOjZyOEGwNlM>
KASUMI-1 cell MoTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;EepZKdmirYnn0bY9vKG:oIHj1cYFvKEuDU2XNTU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yNkCxOkDPxE1? NFHtOoFUSU6JRWK=
NCI-H1755 cell Mn\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk[yTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>? NXzLRWoyW0GQR1XS
human MES-SA cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\rW|NlUW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? MnTUV2FPT0WU
human HCC1395 cell NFnqb2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33SXmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUO5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh2Mkig{txO M{\t[3NCVkeHUh?=
human D-336MG cell MlO2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHnT3FpUW6qaXLpeIlwdiCxZjDoeY1idiCGLUOzOm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe1OEDPxE1? Mm\OV2FPT0WU
CHP-212 cell MnLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5Pzd|IN88US=> NVzMUIlZW0GQR1XS
human KM12 cell MlzyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXLwZWpuUW6qaXLpeIlwdiCxZjDoeY1idiCNTUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTJ5NTFOwG0> MlzyV2FPT0WU
A204 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjnd5dwUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODB3MjFOwG0> Mn75V2FPT0WU
CAL-51 cell NGfkZY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fPb2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODdyOTFOwG0> MkPSV2FPT0WU
human A431 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXS2W4dvUW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJzNjFOwG0> MnjjV2FPT0WU
NCI-H650 cell NEXJ[Y5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTdyODFOwG0> M3nOc3NCVkeHUh?=
A427 cell M2\s[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3XHOmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE6OThizszN MV7TRW5ITVJ?
human 769-P cell M1zIW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\XN2lvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=> M{jqOHNCVkeHUh?=
SW1710 cell NHzKS|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXPnfVNXUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|M{G2JO69VQ>? MYjTRW5ITVJ?
human H4 cell M3jHb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzRXWhKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|k3OyEQvF2= NHLyNlFUSU6JRWK=
HT-1080 cell NFrNcIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnqWplKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUiyJO69VQ>? NXHMeXZiW0GQR1XS
human PANC-03-27 cell Ml7mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNvMEOtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4MEKg{txO MUnTRW5ITVJ?
A375 cells MorkR5l1d3SxeHnjbZR6KGG|c3H5 NE\GbI84OiCq MYPUc5hq[2m2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1yLkG4JO69VQ>? MWGxPVY2PDRyOB?=
human HOP-62 cell NELTdHRHfW6ldHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVgxPzNizszN MY\TRW5ITVJ?
human U031 cell NWXUVHNmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUfQT2JQUW6qaXLpeIlwdiCxZjDoeY1idiCXMEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQTZ7ODFOwG0> NH33U3lUSU6JRWK=
mouse BAF3 cells MmHPVJJwdGmoZYLheIlwdiCjc4PhfS=> NVnRe4JlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJJRz[W6|Zn;ycYVlKHerdHigXm5HOTl6LV\HSnIyKGOxboP0dpVkfCxiSVO1NF0xNjJizszN NWH3eW11OjF7M{[1OFI>
human G-402 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFI2OyEQvF2= M33Se3NCVkeHUh?=
human G-361 cell M1HuZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUDuXGZIUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB6NUOg{txO NU\YT|NZW0GQR1XS
NCI-H810 cell M12yWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVPNS|RFUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkGwNlch|ryP MVHTRW5ITVJ?
NCI-H2030 cell NHzYXWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXXEOlF{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzNFA3KM7:TR?= M33tc3NCVkeHUh?=
human HCT-116 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4PPOGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO NFnkZ|lUSU6JRWK=
human SNU-423 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3PeIhKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT20NlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|NkW3JO69VQ>? MnTJV2FPT0WU
human SCC-4 cell NXS4PXdST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|k3PyEQvF2= MWfTRW5ITVJ?
human SW48 cell NG\NWWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojzTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= MYDTRW5ITVJ?
human SF295 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUjIU2NEUW6qaXLpeIlwdiCxZjDoeY1idiCVRkK5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd{NUeg{txO NYnibXk{W0GQR1XS
MDA-MB-231 cell NITyT49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ6MUCxJO69VQ>? M3W0U3NCVkeHUh?=
A172 cell NWT0cW8zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnrPXVKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6OTVizszN MWLTRW5ITVJ?
human BCPAP cell Ml3KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVzFc5VXUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjl6N{mg{txO M3\IZnNCVkeHUh?=
human COLO-792 cell NWLwSnVbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTl5MjFOwG0> Mlu2V2FPT0WU
human DU-145 cell M3qxdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M17vVGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OTh6OTFOwG0> MoHkV2FPT0WU
NCI-H2122 cell M4LNOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlHHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{Mki1JO69VQ>? NWHzS|J[W0GQR1XS
human SK-UT-1 cell NGTycoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILjUGRKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OUWyJO69VQ>? MWjTRW5ITVJ?
LXF-289 cell NYjKPXRUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MomzTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ojl4NTFOwG0> M3i2O3NCVkeHUh?=
human NCI-H1792 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnHpTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MEm2JO69VQ>? MYfTRW5ITVJ?
MCF7 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?= Mn;LV2FPT0WU
HCT-15 cell NHzrT2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NILCW2pKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2M{Kg{txO NFn2R5dUSU6JRWK=
human NCI-H358 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\CUnNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IN|U5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{W1NUDPxE1? NHPVbZJUSU6JRWK=
human HLE cell MmDtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnhU|FKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4PTJizszN NFfKWoxUSU6JRWK=
human SW1088 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVfJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4QTdizszN NYGxSHJpW0GQR1XS
human K5 cell NGjKNlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkG0PUDPxE1? MXXTRW5ITVJ?
human SR cell NH25cI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIrTNYtKdmirYnn0bY9vKG:oIHj1cYFvKFOUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlU4OSEQvF2= MnXZV2FPT0WU
human Calu-3 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y5OjVizszN NWXvNohqW0GQR1XS
human SK-MEL-30 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\QPHVYUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO5PVE{KM7:TR?= MV\TRW5ITVJ?
human SW780 cell NWTnfmN2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVE1OiEQvF2= MV;TRW5ITVJ?
NCI-H1563 cell NF3Ze5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MofGTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzNEi0JO69VQ>? Ml:zV2FPT0WU
human MKN45 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjR3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVk{OSEQvF2= NIDUSWVUSU6JRWK=
MDA-MB-157 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\s[VhuUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NlAyPSEQvF2= NYPlXlY5W0GQR1XS
human NCI-H522 cell NYTGU3ZDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGOyWnRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO M2fuc3NCVkeHUh?=
human A2780 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\ITY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc2ODNizszN M{HoRXNCVkeHUh?=
human A498 cell M1nRTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXn1VJM6UW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzZ7MzFOwG0> NYfjUIpvW0GQR1XS
human BxPC-3 cell NXzoOlJrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHe5U3ZKdmirYnn0bY9vKG:oIHj1cYFvKEK6UFOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl|Nk[g{txO NVXOOmFCW0GQR1XS
human A2058 cell M1\0fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61Nlg1PCEQvF2= MnXPV2FPT0WU
human PC-14 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYLJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61N|g2PSEQvF2= NFO4NolUSU6JRWK=
human KG-1 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1rnV2lvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN NIPJO21USU6JRWK=
human A375 cell MmS0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDJd5hKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU3OTB|IN88US=> NILvXVFUSU6JRWK=
human SW1783 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M37NZmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> NV3GTHljW0GQR1XS
human MKN1 cell NXrDWmtOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrRTXVKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> NGTNeINUSU6JRWK=
NCI-H1650 cell M4fMW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh7MUdjhKDPxE1? M3jrOXNCVkeHUh?=
human HT-1376 cell M3jFRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF|N{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlkzQTF6IN88US=> M3vsOXNCVkeHUh?=
SW872 cell MlTTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWfGeJdtUW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTR2NUmg{txO NHHKfG1USU6JRWK=
human RT-112 cell MkXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWX2O3lnUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl5NEizJO69VQ>? M4O0NnNCVkeHUh?=
human HT-29 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTWc4VKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0> NYj4N5V[W0GQR1XS
human U-266 cell NFXCb3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWfEXnBQUW6qaXLpeIlwdiCxZjDoeY1idiCXLUK2OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh|MEKg{txO MXXTRW5ITVJ?
human HEL cell Ml;rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfSOWFKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN NHnJdmJUSU6JRWK=
human KU812 cell MnzES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX\4PFAyUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTFzNkSg{txO MWjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 300+ddH2O
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID